Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Summary

Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

Timeline

Start

2019-05-23

Primary completion

2022-04-30

Completion

2023-05-31

Drugs

Indications